社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
junior_daddy
IP属地：未知
+关注
帖子 · 215
帖子 · 215
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
junior_daddy
junior_daddy
·
2021-11-16
Pls like
Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars
Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars.
Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars
看
1,363
回复
1
点赞
3
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-10
Pls like
非常抱歉，此主贴已删除
看
1,900
回复
1
点赞
5
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-09
Pls like
非常抱歉，此主贴已删除
看
1,871
回复
2
点赞
3
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-08
Pls like
Regeneron shares rose 2.2% in premarket trading
Regeneron shares rose 2.2% in premarket trading. Regeneron Pharmaceuticals Inc said on Monday a sing
Regeneron shares rose 2.2% in premarket trading
看
1,495
回复
5
点赞
10
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-08
Pls like
Regeneron shares rose 2.2% in premarket trading
Regeneron shares rose 2.2% in premarket trading. Regeneron Pharmaceuticals Inc said on Monday a sing
Regeneron shares rose 2.2% in premarket trading
看
1,299
回复
1
点赞
9
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-08
Tell me your opinion about this news...
Regeneron shares rose 2.2% in premarket trading
Regeneron shares rose 2.2% in premarket trading. Regeneron Pharmaceuticals Inc said on Monday a sing
Regeneron shares rose 2.2% in premarket trading
看
1,089
回复
评论
点赞
8
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-06
Pls like and comment
Wall St books records, weekly gains on strong jobs report, Pfizer COVID-19 pill cheer
(Reuters) - Wall Street's main indexes scored record closing highs on Friday and booked solid gains
Wall St books records, weekly gains on strong jobs report, Pfizer COVID-19 pill cheer
看
1,590
回复
1
点赞
5
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-04
Pls like 👍
非常抱歉，此主贴已删除
看
1,917
回复
评论
点赞
7
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-03
Pls like
Bed Bath & Beyond’s Stock Surge Revives Retail-Trader Mania
Excitement that’s triggered a surge in Bed Bath & Beyond Inc. shares after a whirl of announcements
Bed Bath & Beyond’s Stock Surge Revives Retail-Trader Mania
看
1,690
回复
评论
点赞
1
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-02
Pls like
Cathie Wood Stands to Make a Lot of Money From Skillz Stock
SKLZ stock, while volatile, has the potential to be a 10-bagger
Cathie Wood Stands to Make a Lot of Money From Skillz Stock
看
1,785
回复
评论
点赞
4
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3574927270640767","uuid":"3574927270640767","gmtCreate":1611834519815,"gmtModify":1625538661889,"name":"junior_daddy","pinyin":"juniordaddyjuniordaddy","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":62,"headSize":417,"tweetSize":215,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.61%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.71%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":871032924,"gmtCreate":1636992768969,"gmtModify":1636992769258,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574927270640767","authorIdStr":"3574927270640767"},"themes":[],"htmlText":"Pls like ","listText":"Pls like ","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/871032924","repostId":"1105194762","repostType":4,"repost":{"id":"1105194762","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636990511,"share":"https://ttm.financial/m/news/1105194762?lang=&edition=full","pubTime":"2021-11-15 23:35","market":"us","language":"en","title":"Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars","url":"https://stock-news.laohu8.com/highlight/detail?id=1105194762","media":"Tiger Newspress","summary":"Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars.","content":"<p>Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars.<img src=\"https://static.tigerbbs.com/201cf466934fa60cc63374e64a0db551\" tg-width=\"772\" tg-height=\"563\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/c5d7f306762ab2851bfef58a237e2d55\" tg-width=\"772\" tg-height=\"560\" referrerpolicy=\"no-referrer\">According to the documents disclosed by the SEC, Musk sold 1.2 million Tesla Motors shares on the 12th. So far, Musk has sold about 6.34 million Tesla Motors shares since November 8. Musk promised to sell 10% of Tesla Motors shares, that is, 17.05 million shares, so Musk has sold only 37.1% of his promise, and needs to sell at least 10.7 million shares of Tesla Motors shares. In addition, Musk hinted that he would sell more Tesla Motors shares; Michael Burry, a \"big bear\", tweeted that Musk only wanted to cash out at a high position.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-15 23:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars.<img src=\"https://static.tigerbbs.com/201cf466934fa60cc63374e64a0db551\" tg-width=\"772\" tg-height=\"563\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/c5d7f306762ab2851bfef58a237e2d55\" tg-width=\"772\" tg-height=\"560\" referrerpolicy=\"no-referrer\">According to the documents disclosed by the SEC, Musk sold 1.2 million Tesla Motors shares on the 12th. So far, Musk has sold about 6.34 million Tesla Motors shares since November 8. Musk promised to sell 10% of Tesla Motors shares, that is, 17.05 million shares, so Musk has sold only 37.1% of his promise, and needs to sell at least 10.7 million shares of Tesla Motors shares. In addition, Musk hinted that he would sell more Tesla Motors shares; Michael Burry, a \"big bear\", tweeted that Musk only wanted to cash out at a high position.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite","TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105194762","content_text":"Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars.According to the documents disclosed by the SEC, Musk sold 1.2 million Tesla Motors shares on the 12th. So far, Musk has sold about 6.34 million Tesla Motors shares since November 8. Musk promised to sell 10% of Tesla Motors shares, that is, 17.05 million shares, so Musk has sold only 37.1% of his promise, and needs to sell at least 10.7 million shares of Tesla Motors shares. In addition, Musk hinted that he would sell more Tesla Motors shares; Michael Burry, a \"big bear\", tweeted that Musk only wanted to cash out at a high position.","news_type":1,"symbols_score_info":{".IXIC":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":1363,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847946892,"gmtCreate":1636475732215,"gmtModify":1636475733291,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574927270640767","authorIdStr":"3574927270640767"},"themes":[],"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/847946892","repostId":"1127189501","repostType":4,"isVote":1,"tweetType":1,"viewCount":1900,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844264318,"gmtCreate":1636432279510,"gmtModify":1636432280528,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574927270640767","authorIdStr":"3574927270640767"},"themes":[],"htmlText":"Pls like ","listText":"Pls like ","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/844264318","repostId":"1121670869","repostType":4,"isVote":1,"tweetType":1,"viewCount":1871,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844034736,"gmtCreate":1636376382655,"gmtModify":1636376383707,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574927270640767","authorIdStr":"3574927270640767"},"themes":[],"htmlText":"Pls like ","listText":"Pls like ","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/844034736","repostId":"1141245956","repostType":4,"repost":{"id":"1141245956","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636375961,"share":"https://ttm.financial/m/news/1141245956?lang=&edition=full","pubTime":"2021-11-08 20:52","market":"us","language":"en","title":"Regeneron shares rose 2.2% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1141245956","media":"Tiger Newspress","summary":"Regeneron shares rose 2.2% in premarket trading.\nRegeneron Pharmaceuticals Inc said on Monday a sing","content":"<p>Regeneron shares rose 2.2% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/1d06980fde1a0bd99affdab9ee4beb4b\" tg-width=\"889\" tg-height=\"603\" width=\"100%\" height=\"auto\">Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.</p>\n<p>The results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.</p>\n<p>Such immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.</p>\n<p>The therapy had previously shown an 81.4% risk reduction during the first month after administration.</p>\n<p>During the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.</p>\n<p>The U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.</p>\n<p>It was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron shares rose 2.2% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron shares rose 2.2% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-08 20:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Regeneron shares rose 2.2% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/1d06980fde1a0bd99affdab9ee4beb4b\" tg-width=\"889\" tg-height=\"603\" width=\"100%\" height=\"auto\">Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.</p>\n<p>The results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.</p>\n<p>Such immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.</p>\n<p>The therapy had previously shown an 81.4% risk reduction during the first month after administration.</p>\n<p>During the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.</p>\n<p>The U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.</p>\n<p>It was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141245956","content_text":"Regeneron shares rose 2.2% in premarket trading.\nRegeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.\nThe results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.\nSuch immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.\nThe therapy had previously shown an 81.4% risk reduction during the first month after administration.\nDuring the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.\nThe U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.\nIt was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.","news_type":1,"symbols_score_info":{"REGN":0.9}},"isVote":1,"tweetType":1,"viewCount":1495,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844034413,"gmtCreate":1636376371509,"gmtModify":1636376372559,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574927270640767","authorIdStr":"3574927270640767"},"themes":[],"htmlText":"Pls like ","listText":"Pls like ","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/844034413","repostId":"1141245956","repostType":4,"repost":{"id":"1141245956","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636375961,"share":"https://ttm.financial/m/news/1141245956?lang=&edition=full","pubTime":"2021-11-08 20:52","market":"us","language":"en","title":"Regeneron shares rose 2.2% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1141245956","media":"Tiger Newspress","summary":"Regeneron shares rose 2.2% in premarket trading.\nRegeneron Pharmaceuticals Inc said on Monday a sing","content":"<p>Regeneron shares rose 2.2% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/1d06980fde1a0bd99affdab9ee4beb4b\" tg-width=\"889\" tg-height=\"603\" width=\"100%\" height=\"auto\">Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.</p>\n<p>The results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.</p>\n<p>Such immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.</p>\n<p>The therapy had previously shown an 81.4% risk reduction during the first month after administration.</p>\n<p>During the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.</p>\n<p>The U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.</p>\n<p>It was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron shares rose 2.2% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron shares rose 2.2% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-08 20:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Regeneron shares rose 2.2% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/1d06980fde1a0bd99affdab9ee4beb4b\" tg-width=\"889\" tg-height=\"603\" width=\"100%\" height=\"auto\">Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.</p>\n<p>The results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.</p>\n<p>Such immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.</p>\n<p>The therapy had previously shown an 81.4% risk reduction during the first month after administration.</p>\n<p>During the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.</p>\n<p>The U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.</p>\n<p>It was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141245956","content_text":"Regeneron shares rose 2.2% in premarket trading.\nRegeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.\nThe results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.\nSuch immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.\nThe therapy had previously shown an 81.4% risk reduction during the first month after administration.\nDuring the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.\nThe U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.\nIt was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.","news_type":1,"symbols_score_info":{"REGN":0.9}},"isVote":1,"tweetType":1,"viewCount":1299,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844034236,"gmtCreate":1636376360851,"gmtModify":1636376361825,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574927270640767","authorIdStr":"3574927270640767"},"themes":[],"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844034236","repostId":"1141245956","repostType":4,"repost":{"id":"1141245956","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636375961,"share":"https://ttm.financial/m/news/1141245956?lang=&edition=full","pubTime":"2021-11-08 20:52","market":"us","language":"en","title":"Regeneron shares rose 2.2% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1141245956","media":"Tiger Newspress","summary":"Regeneron shares rose 2.2% in premarket trading.\nRegeneron Pharmaceuticals Inc said on Monday a sing","content":"<p>Regeneron shares rose 2.2% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/1d06980fde1a0bd99affdab9ee4beb4b\" tg-width=\"889\" tg-height=\"603\" width=\"100%\" height=\"auto\">Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.</p>\n<p>The results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.</p>\n<p>Such immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.</p>\n<p>The therapy had previously shown an 81.4% risk reduction during the first month after administration.</p>\n<p>During the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.</p>\n<p>The U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.</p>\n<p>It was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron shares rose 2.2% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron shares rose 2.2% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-08 20:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Regeneron shares rose 2.2% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/1d06980fde1a0bd99affdab9ee4beb4b\" tg-width=\"889\" tg-height=\"603\" width=\"100%\" height=\"auto\">Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.</p>\n<p>The results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.</p>\n<p>Such immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.</p>\n<p>The therapy had previously shown an 81.4% risk reduction during the first month after administration.</p>\n<p>During the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.</p>\n<p>The U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.</p>\n<p>It was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141245956","content_text":"Regeneron shares rose 2.2% in premarket trading.\nRegeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.\nThe results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.\nSuch immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.\nThe therapy had previously shown an 81.4% risk reduction during the first month after administration.\nDuring the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.\nThe U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.\nIt was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.","news_type":1,"symbols_score_info":{"REGN":0.9}},"isVote":1,"tweetType":1,"viewCount":1089,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842674025,"gmtCreate":1636175962142,"gmtModify":1636175963148,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574927270640767","authorIdStr":"3574927270640767"},"themes":[],"htmlText":"Pls like and comment ","listText":"Pls like and comment ","text":"Pls like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/842674025","repostId":"1173813098","repostType":4,"repost":{"id":"1173813098","kind":"news","pubTimestamp":1636156499,"share":"https://ttm.financial/m/news/1173813098?lang=&edition=full","pubTime":"2021-11-06 07:54","market":"us","language":"en","title":"Wall St books records, weekly gains on strong jobs report, Pfizer COVID-19 pill cheer","url":"https://stock-news.laohu8.com/highlight/detail?id=1173813098","media":"Reuters","summary":"(Reuters) - Wall Street's main indexes scored record closing highs on Friday and booked solid gains ","content":"<p>(Reuters) - Wall Street's main indexes scored record closing highs on Friday and booked solid gains for the week following a strong U.S. jobs report and positive data for Pfizer's experimental pill against COVID-19.</p>\n<p>The S&P 500 and the Nasdaq notched record high closes for their seventh straight sessions, while the Dow Jones Industrial Average also closed at a record. All three indexes posted weekly gains for their fifth straight weeks.</p>\n<p>The Labor Department report showed U.S. employment increased more than expected in October as the headwind from the surge in COVID-19 infections over the summer subsided.</p>\n<p>A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease. Pfizer shares jumped about 11%.</p>\n<p>The news kept the run going for equities after investors earlier in the week digested the Federal Reserve's decision to start reducing its monthly bond purchases put in place to support the economy.</p>\n<p>\"Momentum that we have seen this week has continued, and the jobs report and the Pfizer announcement certainly are providing positive datapoints for investors to put more money into the market right now,” said Chuck Carlson, chief executive officer at Horizon Investment Services in Hammond, Indiana.</p>\n<p>The Dow Jones Industrial Average rose 203.72 points, or 0.56%, to 36,327.95, the S&P 500 gained 17.47 points, or 0.37%, to 4,697.53 and the Nasdaq Composite added 31.28 points, or 0.2%, to 15,971.59.</p>\n<p>For the week, the S&P 500 rose 2%, the Dow added 1.42%, while the Nasdaq gained 3.05%.</p>\n<p>Travel stocks rose following Pfizer's announcement, with the S&P 1500 airlines index climbing 7%, and cruise operators Carnival Corp, Royal Caribbean Cruises and Norwegian Cruise rising between about 8% to 9%.</p>\n<p>\"Still early to be definitive but this (pill) looks like a true game changer for many industries like leisure and transportation, you're seeing it reflected in the prices,\" said Andre Bakhos, managing director at New Vines Capital LLC in Bernardsville, New Jersey.</p>\n<p>Among S&P 500 sectors, energy and industrials led the way, rising 1.4% and 1%, respectively.</p>\n<p>Healthcare was the only sector that ended negative, falling 1%. The Pfizer news weighed on shares of competitors such as Merck, which fell nearly 10%, and COVID-19 vaccine makers such as Moderna, which slumped 16.6%.</p>\n<p>Shares of so-called \"stay-at-home\" names fell, with <a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications down 6.2% and Netflix Inc off 3.4%.</p>\n<p>Better-than-expected third-quarter earnings have helped lift sentiment for equities. With about 440 companies having reported, S&P 500 earnings are expected to have climbed 41.5% in the third quarter from a year earlier, according to Refinitiv IBES.</p>\n<p>Pinterest Inc shares climbed 5.9% after the company's strong fourth-quarter revenue forecast.</p>\n<p>Peloton Interactive Inc shares slumped 35.3% after the company slashed its full-year sales forecast by up to $1 billion.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.16-to-1 ratio; on Nasdaq, a 1.22-to-1 ratio favored advancers.</p>\n<p>The S&P 500 posted 83 new 52-week highs and two new lows; the Nasdaq Composite recorded 303 new highs and 80 new lows.</p>\n<p>About 11.5 billion shares changed hands in U.S. exchanges, compared with the 10.5 billion daily average over the last 20 sessions.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall St books records, weekly gains on strong jobs report, Pfizer COVID-19 pill cheer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall St books records, weekly gains on strong jobs report, Pfizer COVID-19 pill cheer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-06 07:54 GMT+8 <a href=https://www.streetinsider.com/dr/news.php?id=19167545><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Wall Street's main indexes scored record closing highs on Friday and booked solid gains for the week following a strong U.S. jobs report and positive data for Pfizer's experimental pill ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19167545\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19167545","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173813098","content_text":"(Reuters) - Wall Street's main indexes scored record closing highs on Friday and booked solid gains for the week following a strong U.S. jobs report and positive data for Pfizer's experimental pill against COVID-19.\nThe S&P 500 and the Nasdaq notched record high closes for their seventh straight sessions, while the Dow Jones Industrial Average also closed at a record. All three indexes posted weekly gains for their fifth straight weeks.\nThe Labor Department report showed U.S. employment increased more than expected in October as the headwind from the surge in COVID-19 infections over the summer subsided.\nA trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease. Pfizer shares jumped about 11%.\nThe news kept the run going for equities after investors earlier in the week digested the Federal Reserve's decision to start reducing its monthly bond purchases put in place to support the economy.\n\"Momentum that we have seen this week has continued, and the jobs report and the Pfizer announcement certainly are providing positive datapoints for investors to put more money into the market right now,” said Chuck Carlson, chief executive officer at Horizon Investment Services in Hammond, Indiana.\nThe Dow Jones Industrial Average rose 203.72 points, or 0.56%, to 36,327.95, the S&P 500 gained 17.47 points, or 0.37%, to 4,697.53 and the Nasdaq Composite added 31.28 points, or 0.2%, to 15,971.59.\nFor the week, the S&P 500 rose 2%, the Dow added 1.42%, while the Nasdaq gained 3.05%.\nTravel stocks rose following Pfizer's announcement, with the S&P 1500 airlines index climbing 7%, and cruise operators Carnival Corp, Royal Caribbean Cruises and Norwegian Cruise rising between about 8% to 9%.\n\"Still early to be definitive but this (pill) looks like a true game changer for many industries like leisure and transportation, you're seeing it reflected in the prices,\" said Andre Bakhos, managing director at New Vines Capital LLC in Bernardsville, New Jersey.\nAmong S&P 500 sectors, energy and industrials led the way, rising 1.4% and 1%, respectively.\nHealthcare was the only sector that ended negative, falling 1%. The Pfizer news weighed on shares of competitors such as Merck, which fell nearly 10%, and COVID-19 vaccine makers such as Moderna, which slumped 16.6%.\nShares of so-called \"stay-at-home\" names fell, with Zoom Video Communications down 6.2% and Netflix Inc off 3.4%.\nBetter-than-expected third-quarter earnings have helped lift sentiment for equities. With about 440 companies having reported, S&P 500 earnings are expected to have climbed 41.5% in the third quarter from a year earlier, according to Refinitiv IBES.\nPinterest Inc shares climbed 5.9% after the company's strong fourth-quarter revenue forecast.\nPeloton Interactive Inc shares slumped 35.3% after the company slashed its full-year sales forecast by up to $1 billion.\nAdvancing issues outnumbered declining ones on the NYSE by a 2.16-to-1 ratio; on Nasdaq, a 1.22-to-1 ratio favored advancers.\nThe S&P 500 posted 83 new 52-week highs and two new lows; the Nasdaq Composite recorded 303 new highs and 80 new lows.\nAbout 11.5 billion shares changed hands in U.S. exchanges, compared with the 10.5 billion daily average over the last 20 sessions.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1590,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846055534,"gmtCreate":1636036536957,"gmtModify":1636036936332,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574927270640767","authorIdStr":"3574927270640767"},"themes":[],"htmlText":"Pls like 👍 ","listText":"Pls like 👍 ","text":"Pls like 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846055534","repostId":"1144131531","repostType":4,"isVote":1,"tweetType":1,"viewCount":1917,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848062168,"gmtCreate":1635948641869,"gmtModify":1635948740884,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574927270640767","authorIdStr":"3574927270640767"},"themes":[],"htmlText":"Pls like ","listText":"Pls like ","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848062168","repostId":"1100947774","repostType":2,"repost":{"id":"1100947774","kind":"news","pubTimestamp":1635943689,"share":"https://ttm.financial/m/news/1100947774?lang=&edition=full","pubTime":"2021-11-03 20:48","market":"us","language":"en","title":"Bed Bath & Beyond’s Stock Surge Revives Retail-Trader Mania","url":"https://stock-news.laohu8.com/highlight/detail?id=1100947774","media":"Bloomberg","summary":"Excitement that’s triggered a surge in Bed Bath & Beyond Inc. shares after a whirl of announcements ","content":"<p>Excitement that’s triggered a surge in Bed Bath & Beyond Inc. shares after a whirl of announcements has fueled a rally in other retail-trader favorites, causing chatrooms like StockTwits to light up with optimistic comments.</p>\n<p>The retailer soared 55% in trading before Wednesday’s U.S. stock-market open, the day after releasing plans to help its turnaround. The advance triggered gains in original meme stocks like AMC Entertainment Holdings Inc.,GameStop Corp., and Koss Corp. in early trading.</p>\n<p>Retailer Bed Bath & Beyond was among the many so-called meme stocks that saw meteoric gains turn to pain earlier this year amid concern about the company’s fundamentals. Shares closed at their lowest level in more than a year last week amid muted expectations afterquarterly sales missedestimates.</p>\n<p><img src=\"https://static.tigerbbs.com/7f583ea80b3b20cd507d78e8311965aa\" tg-width=\"1200\" tg-height=\"675\" width=\"100%\" height=\"auto\"></p>\n<p>This week’s resurgence is likely fueled in part by FOMO -- fear of missing out -- and those who have bought into the investing mantra of YOLO -- you only live once. The appetite for risky investments among retail traders appears to be rising, according to Vanda Research.</p>\n<p>The red-hot rally comes just a day after Avis Budget Group Inc. more than doubled amid a flurry of retail-crazed trading. While investors cheered the surges, Wall Street analysts voiced warnings that the gains ignore reality.</p>\n<p>Loop Capital Markets’ Anthony Chukumba downgraded Bed Bath & Beyond to sell, saying the purveyor of home goods has “lost market share, mind share, and consumer relevance” with none of the updates materially changing his skeptical view on the stock. Avis, which fell about 10% in early trading,was downgraded by both JPMorgan Chase & Co. and Deutsche Bank AG, who warned the company’s $20 billion valuation wasn’t realistic.</p>\n<p>To be fair, Wall Street has warned that valuations for cult-favorites like AMC Entertainment and GameStop have been divorced from reality for more than nine months. But that hasn’t stopped retail traders and hedge funds looking to strike it rich quick.</p>\n<p>For investors who got in before the start of 2021, it’s been lucrative. Movie-theater company AMC Entertainment is up 1,730% and GameStop is up roughly 1,000%, while newer meme stocks like the Donald Trump-tied SPAC, Digital World Acquisition Corp., and Ocugen Inc. have returned more than 500% apiece.</p>\n<p>A basket of 37 retail-trader favorites tracked by Bloomberg News has climbed 5.8% this week, besting a 0.6% return for the S&P 500 Index. The group of stocks preferred by day traders rallied 4.9% on Monday for the best day since late August.</p>\n<p>Here are some retail-favorites that are seeing notable gains before Wednesday’s market open</p>\n<ul>\n <li>AMC Entertainment climbs 5%</li>\n <li>GameStop rises 3.8%</li>\n <li>Koss Corp. rises about 4%</li>\n <li>Naked Brand jumps 3.3%</li>\n</ul>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bed Bath & Beyond’s Stock Surge Revives Retail-Trader Mania</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBed Bath & Beyond’s Stock Surge Revives Retail-Trader Mania\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-03 20:48 GMT+8 <a href=https://www.bloomberg.com/news/articles/2021-11-03/bed-bath-beyond-s-stock-surge-revives-retail-trader-mania?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Excitement that’s triggered a surge in Bed Bath & Beyond Inc. shares after a whirl of announcements has fueled a rally in other retail-trader favorites, causing chatrooms like StockTwits to light up ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-03/bed-bath-beyond-s-stock-surge-revives-retail-trader-mania?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线","OCGN":"Ocugen","CAR":"安飞士","GME":"游戏驿站","KOSS":"高斯电子","BBBY":"3B家居"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-03/bed-bath-beyond-s-stock-surge-revives-retail-trader-mania?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100947774","content_text":"Excitement that’s triggered a surge in Bed Bath & Beyond Inc. shares after a whirl of announcements has fueled a rally in other retail-trader favorites, causing chatrooms like StockTwits to light up with optimistic comments.\nThe retailer soared 55% in trading before Wednesday’s U.S. stock-market open, the day after releasing plans to help its turnaround. The advance triggered gains in original meme stocks like AMC Entertainment Holdings Inc.,GameStop Corp., and Koss Corp. in early trading.\nRetailer Bed Bath & Beyond was among the many so-called meme stocks that saw meteoric gains turn to pain earlier this year amid concern about the company’s fundamentals. Shares closed at their lowest level in more than a year last week amid muted expectations afterquarterly sales missedestimates.\n\nThis week’s resurgence is likely fueled in part by FOMO -- fear of missing out -- and those who have bought into the investing mantra of YOLO -- you only live once. The appetite for risky investments among retail traders appears to be rising, according to Vanda Research.\nThe red-hot rally comes just a day after Avis Budget Group Inc. more than doubled amid a flurry of retail-crazed trading. While investors cheered the surges, Wall Street analysts voiced warnings that the gains ignore reality.\nLoop Capital Markets’ Anthony Chukumba downgraded Bed Bath & Beyond to sell, saying the purveyor of home goods has “lost market share, mind share, and consumer relevance” with none of the updates materially changing his skeptical view on the stock. Avis, which fell about 10% in early trading,was downgraded by both JPMorgan Chase & Co. and Deutsche Bank AG, who warned the company’s $20 billion valuation wasn’t realistic.\nTo be fair, Wall Street has warned that valuations for cult-favorites like AMC Entertainment and GameStop have been divorced from reality for more than nine months. But that hasn’t stopped retail traders and hedge funds looking to strike it rich quick.\nFor investors who got in before the start of 2021, it’s been lucrative. Movie-theater company AMC Entertainment is up 1,730% and GameStop is up roughly 1,000%, while newer meme stocks like the Donald Trump-tied SPAC, Digital World Acquisition Corp., and Ocugen Inc. have returned more than 500% apiece.\nA basket of 37 retail-trader favorites tracked by Bloomberg News has climbed 5.8% this week, besting a 0.6% return for the S&P 500 Index. The group of stocks preferred by day traders rallied 4.9% on Monday for the best day since late August.\nHere are some retail-favorites that are seeing notable gains before Wednesday’s market open\n\nAMC Entertainment climbs 5%\nGameStop rises 3.8%\nKoss Corp. rises about 4%\nNaked Brand jumps 3.3%","news_type":1,"symbols_score_info":{"AMC":0.9,"BBBY":0.9,"CAR":0.9,"DWAC":0.9,"GME":0.9,"KOSS":0.9,"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":1690,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843537042,"gmtCreate":1635840741218,"gmtModify":1635840741544,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574927270640767","authorIdStr":"3574927270640767"},"themes":[],"htmlText":"Pls like ","listText":"Pls like ","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843537042","repostId":"1129449747","repostType":4,"repost":{"id":"1129449747","kind":"news","pubTimestamp":1635839802,"share":"https://ttm.financial/m/news/1129449747?lang=&edition=full","pubTime":"2021-11-02 15:56","market":"us","language":"en","title":"Cathie Wood Stands to Make a Lot of Money From Skillz Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1129449747","media":"InvestorPlace","summary":"SKLZ stock, while volatile, has the potential to be a 10-bagger","content":"<p>The <b>Ark Innovation ETF</b>(NYSEARCA:<b><u>ARKK</u></b>) bought2.1 million shares of <b>Skillz</b>(NYSE:<b><u>SKLZ</u></b>) on Oct. 21., according to <i>24/7 Wall St., t</i>he SKLZ stock buy brings the ETF’s total holdings of the esports gaming platform company to 13.3 million shares.</p>\n<p>Although the SKILLZ position is only good for 0.70% of the ETF’s $19.4 billion in total assets, it’s got a shot at becoming one of the star portfolio manager’s biggest successes.</p>\n<p>Well, maybe not <b>Tesla</b>(NASDAQ:<b><u>TSLA</u></b>) big, but significant all the same. For example, if Skillz stock miraculously reverted to its all-time high of $46.30, which it hit in February, the ETF’s Skillz shares would be worth $617.2 million and a weighting of 3.18%. That’s good for 11th position. Currently, it’s 34th.</p>\n<p>Since the share purchase, SKLZ stock has gained almost 17% through the second-last trading day in October. It’s on a roll.</p>\n<p><b>SKLZ Stock: Where to From Here?</b></p>\n<p>There is no doubt the short-sellers are battling it out with the Reddit crowd over the ultimate direction of Skillz stock. More than 555 million shares,or 23% of its total, are sold short.</p>\n<p>A short squeeze seems possible in the near term, but the reality, like many stocks, is that neither side appears ready to take the bull by the horns.</p>\n<p>In the interim, Wood keeps building her position in the company.</p>\n<p>Over at the <b>ARK Next Generation Internet ETF</b>(NYSEARCA:<b><u>ARKW</u></b>), the fund holds 7.0 million shares of Skillz, good for 22nd position in ARKW. So, put those two positions together, move up to $46.30 in the blink of an eye, and Ark Investment Management is sitting on a $1 billion investment.</p>\n<p>And it could get even better than that.</p>\n<p>The portfolio manager has been selling little bits of Tesla as it’s moved over $1,000 in recent weeks. On Oct. 21 and 22, she sold more than 126,000 shares for proceeds of $114 million. Then on Oct. 25, she sold another 22,598 shares of Tesla.</p>\n<p>Those proceeds have to go into other stocks at some point.</p>\n<p><b>Another Successful Quarter of Sales Growth</b></p>\n<p>Skillz has been able to string together 22 consecutive quarters of sales growth — profits, or should I say losses, are another story altogether — and looks likely to ring in a 23rd consecutive quarter of strong sales growth when it reports earnings in early November.</p>\n<p>The analyst estimate for Q3 2021 is $102.3 million. The company’s full-year guidance is for $375 million. That doesn’t even include its acquisition of Aarki.</p>\n<p>In July, I suggested that Aarki insiders should hang on to the four million shares of SKLZ stock they got as part of the sale to Skillz.</p>\n<p>“Between Wood’s ownership, the fact that Skillz came public through a Jeff Sagansky and Harry Sloan SPAC, and the company participates in mobile gaming, one of the hottest industries around, I think the risk-reward proposition is excellent between $15 and $20,” I wrote on July 14.</p>\n<p>“If you buy at current prices, be prepared for a lot of volatility. I would not be surprised if it tests $15 on the downside again soon. If you do buy now, I’d keep some cash on the sidelines so you can buy some more at $15 or less.”</p>\n<p>I also said that adding Aarki to the mix should help Skillz keep generating more revenue from users, commonly referred to as ARPU, or average revenue per user.</p>\n<p>In the second quarter, it reported an ARPU of $12.46. That was 20.4% higher than the first quarter of 2021. So if it can keep moving the needle higher, you can be sure the profits will start to roll.</p>\n<p><i>InvestorPlace’s</i> Alex Sirois believes that investors should wait to buy until after the third-quarter results are released before making a move.</p>\n<p>“Losses nearly quadrupled in Q2 on a year-over-year basis, rising to $79.6 million from $20.2 million a year ago. It was a similar story in the first quarter, with the company’s net loss widening to $53.6 million from $15.5 million in the first quarter of 2021,” Sirois stated on Oct. 28.</p>\n<p>“So, although analysts are predicting strong revenue growth, I wouldn’t jump into SKLZ stock until the company proves it can control its losses.”</p>\n<p>While I get where my colleague is coming from, the company has plenty of cash ($692.8 million) to get it through the rest of this fiscal year and all of fiscal 2022. So I would be squarely fixed on top-line growth and ARPU.</p>\n<p>If these two numbers grew sequentially and year-over-year by double digits, all’s good with the company. Worrying about losses at this point is how investors miss out and quality growth stories like Skillz.</p>\n<p>And, besides, as my colleague says, there’s a lot of good things happening in its product development at the moment. So avoid the noise and focus on what matters for SKLZ stock in the near term.</p>\n<p>While Cathie Wood has been both a buyer and seller of SKLZ stock, ultimately, I believe she’ll make out like a bandit.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Stands to Make a Lot of Money From Skillz Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Stands to Make a Lot of Money From Skillz Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-02 15:56 GMT+8 <a href=https://investorplace.com/2021/11/cathie-wood-stands-to-make-a-lot-of-money-from-skillz-sklz-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Ark Innovation ETF(NYSEARCA:ARKK) bought2.1 million shares of Skillz(NYSE:SKLZ) on Oct. 21., according to 24/7 Wall St., the SKLZ stock buy brings the ETF’s total holdings of the esports gaming ...</p>\n\n<a href=\"https://investorplace.com/2021/11/cathie-wood-stands-to-make-a-lot-of-money-from-skillz-sklz-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SKLZ":"Skillz Inc"},"source_url":"https://investorplace.com/2021/11/cathie-wood-stands-to-make-a-lot-of-money-from-skillz-sklz-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129449747","content_text":"The Ark Innovation ETF(NYSEARCA:ARKK) bought2.1 million shares of Skillz(NYSE:SKLZ) on Oct. 21., according to 24/7 Wall St., the SKLZ stock buy brings the ETF’s total holdings of the esports gaming platform company to 13.3 million shares.\nAlthough the SKILLZ position is only good for 0.70% of the ETF’s $19.4 billion in total assets, it’s got a shot at becoming one of the star portfolio manager’s biggest successes.\nWell, maybe not Tesla(NASDAQ:TSLA) big, but significant all the same. For example, if Skillz stock miraculously reverted to its all-time high of $46.30, which it hit in February, the ETF’s Skillz shares would be worth $617.2 million and a weighting of 3.18%. That’s good for 11th position. Currently, it’s 34th.\nSince the share purchase, SKLZ stock has gained almost 17% through the second-last trading day in October. It’s on a roll.\nSKLZ Stock: Where to From Here?\nThere is no doubt the short-sellers are battling it out with the Reddit crowd over the ultimate direction of Skillz stock. More than 555 million shares,or 23% of its total, are sold short.\nA short squeeze seems possible in the near term, but the reality, like many stocks, is that neither side appears ready to take the bull by the horns.\nIn the interim, Wood keeps building her position in the company.\nOver at the ARK Next Generation Internet ETF(NYSEARCA:ARKW), the fund holds 7.0 million shares of Skillz, good for 22nd position in ARKW. So, put those two positions together, move up to $46.30 in the blink of an eye, and Ark Investment Management is sitting on a $1 billion investment.\nAnd it could get even better than that.\nThe portfolio manager has been selling little bits of Tesla as it’s moved over $1,000 in recent weeks. On Oct. 21 and 22, she sold more than 126,000 shares for proceeds of $114 million. Then on Oct. 25, she sold another 22,598 shares of Tesla.\nThose proceeds have to go into other stocks at some point.\nAnother Successful Quarter of Sales Growth\nSkillz has been able to string together 22 consecutive quarters of sales growth — profits, or should I say losses, are another story altogether — and looks likely to ring in a 23rd consecutive quarter of strong sales growth when it reports earnings in early November.\nThe analyst estimate for Q3 2021 is $102.3 million. The company’s full-year guidance is for $375 million. That doesn’t even include its acquisition of Aarki.\nIn July, I suggested that Aarki insiders should hang on to the four million shares of SKLZ stock they got as part of the sale to Skillz.\n“Between Wood’s ownership, the fact that Skillz came public through a Jeff Sagansky and Harry Sloan SPAC, and the company participates in mobile gaming, one of the hottest industries around, I think the risk-reward proposition is excellent between $15 and $20,” I wrote on July 14.\n“If you buy at current prices, be prepared for a lot of volatility. I would not be surprised if it tests $15 on the downside again soon. If you do buy now, I’d keep some cash on the sidelines so you can buy some more at $15 or less.”\nI also said that adding Aarki to the mix should help Skillz keep generating more revenue from users, commonly referred to as ARPU, or average revenue per user.\nIn the second quarter, it reported an ARPU of $12.46. That was 20.4% higher than the first quarter of 2021. So if it can keep moving the needle higher, you can be sure the profits will start to roll.\nInvestorPlace’s Alex Sirois believes that investors should wait to buy until after the third-quarter results are released before making a move.\n“Losses nearly quadrupled in Q2 on a year-over-year basis, rising to $79.6 million from $20.2 million a year ago. It was a similar story in the first quarter, with the company’s net loss widening to $53.6 million from $15.5 million in the first quarter of 2021,” Sirois stated on Oct. 28.\n“So, although analysts are predicting strong revenue growth, I wouldn’t jump into SKLZ stock until the company proves it can control its losses.”\nWhile I get where my colleague is coming from, the company has plenty of cash ($692.8 million) to get it through the rest of this fiscal year and all of fiscal 2022. So I would be squarely fixed on top-line growth and ARPU.\nIf these two numbers grew sequentially and year-over-year by double digits, all’s good with the company. Worrying about losses at this point is how investors miss out and quality growth stories like Skillz.\nAnd, besides, as my colleague says, there’s a lot of good things happening in its product development at the moment. So avoid the noise and focus on what matters for SKLZ stock in the near term.\nWhile Cathie Wood has been both a buyer and seller of SKLZ stock, ultimately, I believe she’ll make out like a bandit.","news_type":1,"symbols_score_info":{"SKLZ":0.9}},"isVote":1,"tweetType":1,"viewCount":1785,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}